What did TRUSCREEN GROUP LIMITED announce?

TRUSCREEN GROUP LIMITED (NZX: TRU) filed “Retirement of Director” with NZX on 31 March 2026, as a director departure announcement.

From the announcement:“Truscreen Group Limited (NZX/ASX: TRU) (TruScreen or Company) wish to advise that Mr Christopher Horn has informed the Company of his intention to retire as a non-executive director following the filing of the Company’s Preliminary Final results, expected to be on or around 31 May 2026.”
When was it filed?
31 March 2026
Where is the original?
NZX announcement
TRUSCREEN GROUP LIMITED logo

Retirement of Director

Director Departure31 March 2026TRUIndustrials

NZX/ASX Announcement
1 April 2026

Retirement of Director

Truscreen Group Limited (NZX/ASX: TRU) (TruScreen or Company) wish to advise that Mr Christopher Horn

has informed the Company of his intention to retire as a non-executive director following the filing of the

Company’s Preliminary Final results, expected to be on or around 31 May 2026.


Chris was appointed a non-executive director of TruScreen on 1 November 2013 and was part of the team

instrumental in the Company’s progression, including listing of the Company on the NZAX in November 2014,

transition to the main board NZX in December 2018, and dual listing on the ASX in January 2021.


Chris has served the Company as an independent non-executive director, and Chairman of the Audit

Committee. Chris was previously a senior partner of KPMG and brought to TruScreen, a wealth of business

experience across various industries and geography. He made a significant contribution to the Company’s

financial reporting, corporate governance, and the ongoing commercial development of the TruScreen cervical

cancer screening technology.


Executive Chairman Tony Ho said, “Chris should be proud of his contribution, over 13 years, to be part of the

commercialisation journey of TruScreen as a woman’s health start up to where it is to-day, a leading global

company recognized and endorsed by WHO as an important AI enabled cervical cancer technology that will

assist WHO to achieve its 90-70-90 objectives towards eliminating cervical cancer. On behalf of the Board and

management of the Company, I thank Chris for his significant contributions and counsel over many years. I

understand that this is Chris’ remaining professional engagement and wish Chris all the best in his retirement.

No doubt his golf handicap will improve.”


On Chris’s retirement, the Board will appoint Ms Christine Pears as Chair of the Audit Committee and will appoint

a replacement Australian based Non-Executive Director in due course.


Authorised by the Board for filing with the NZX/ASX.





Anthony Ho

Executive Chairman



For more information, visit www.truscreen.com or contact:

Tony Ho

Executive Chairman

tonyho@truscreen.com


Guy Robertson

Chief Financial Officer

guyrobertson@truscreen.com




About TruScreen:


TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and

manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via

measurements of the low level of optical and electrical stimuli.

TruScreen’s cervical screening technology enables cervical screening, negating sampling and

processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly,

specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra

®

, is registered as a primary screening device for cervical cancer

screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA

(Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS

(Mexico). It has Ministry of Health approval for use in Vietnam, Israel, Ukraine, and the Philippines,

among others and has distributors in 29 countries. In 2021, TruScreen established a manufacturing

facility in China for devices marketed and sold in China.

TruScreen technology is recognised in CSCCP’s (Chinese Society for Colposcopy and Cervical

Pathology) China Cervical Cancer Screening Management Guidelines and the COGA Blue Book.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National

Technical List, for use in Vietnam’s public and private healthcare sectors and in 2024 was added to the

Russian guidelines for the screening of cervical cancer.

In financial year 2024 alone, over 200,000* examinations were performed with the TruScreen device. To

date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and

Saudi Arabia. TruScreen’s vision is “A world without the cervical cancer”.

To learn more, please visit: www.truscreen.com/.

*Based on Single Use Sensor sales.



About DaltonBio:


DALTON BioSciences ("DALTONbio") is a global, innovative medical technology company focusing on

in vitro diagnosis (IVD) in women's health and oncology. DALTONbio is the leader in human

papillomavirus (HPV) nucleic acid testing and comprehensive cervical cancer detection and screening.

Its HPV DNA detection kits (DH HPV test series) are the world's only products based on its third-

generation proprietary hybrid-capture technology, which provides HPV genotyping without requiring

nucleic acid extractions and amplifications. This technology is well-suited for the detection of high-risk

types of HPV and cervical cancer screening. DALTONbio’s exceptional, clinically proven products have

served tens of millions of lives in the world. They have aided health professionals in detecting,

diagnosing, and treating illnesses earlier and more effectively, resulting in healthier people everywhere,

every day.

To learn more, please visit: www.daltonbio.com/.

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.